CN1660261A - 复方麦芪注射剂及制备方法 - Google Patents
复方麦芪注射剂及制备方法 Download PDFInfo
- Publication number
- CN1660261A CN1660261A CN 200410081470 CN200410081470A CN1660261A CN 1660261 A CN1660261 A CN 1660261A CN 200410081470 CN200410081470 CN 200410081470 CN 200410081470 A CN200410081470 A CN 200410081470A CN 1660261 A CN1660261 A CN 1660261A
- Authority
- CN
- China
- Prior art keywords
- injection
- total
- wheat
- radix astragali
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002347 injection Methods 0.000 title claims abstract description 83
- 239000007924 injection Substances 0.000 title claims abstract description 83
- 150000001875 compounds Chemical class 0.000 title claims description 56
- 238000002360 preparation method Methods 0.000 title claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000008215 water for injection Substances 0.000 claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 12
- 229940090044 injection Drugs 0.000 claims description 79
- 239000009636 Huang Qi Substances 0.000 claims description 63
- 210000004369 blood Anatomy 0.000 claims description 49
- 239000008280 blood Substances 0.000 claims description 49
- 239000000284 extract Substances 0.000 claims description 42
- 150000004676 glycans Chemical class 0.000 claims description 41
- 229920001282 polysaccharide Polymers 0.000 claims description 41
- 239000005017 polysaccharide Substances 0.000 claims description 41
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 claims description 39
- 229930182490 saponin Natural products 0.000 claims description 39
- 235000017709 saponins Nutrition 0.000 claims description 39
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 claims description 39
- 229930003944 flavone Natural products 0.000 claims description 38
- 235000011949 flavones Nutrition 0.000 claims description 38
- 241000209140 Triticum Species 0.000 claims description 37
- 235000021307 Triticum Nutrition 0.000 claims description 37
- 150000007949 saponins Chemical class 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 36
- 150000002213 flavones Chemical class 0.000 claims description 33
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 claims description 24
- 235000021286 stilbenes Nutrition 0.000 claims description 24
- 206010008118 cerebral infarction Diseases 0.000 claims description 22
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 208000011580 syndromic disease Diseases 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 210000004072 lung Anatomy 0.000 claims description 18
- 208000006011 Stroke Diseases 0.000 claims description 17
- 230000017531 blood circulation Effects 0.000 claims description 17
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 16
- 229960004756 ethanol Drugs 0.000 claims description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 15
- 239000003172 expectorant agent Substances 0.000 claims description 15
- 230000001737 promoting effect Effects 0.000 claims description 15
- 230000003419 expectorant effect Effects 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000007689 inspection Methods 0.000 claims description 14
- 230000002685 pulmonary effect Effects 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 13
- 210000001367 artery Anatomy 0.000 claims description 12
- 210000003462 vein Anatomy 0.000 claims description 12
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 11
- 230000007812 deficiency Effects 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 208000011191 Pulmonary vascular disease Diseases 0.000 claims description 10
- 230000001631 hypertensive effect Effects 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 206010002383 Angina Pectoris Diseases 0.000 claims description 9
- 206010008479 Chest Pain Diseases 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 208000006820 Arthralgia Diseases 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 230000000302 ischemic effect Effects 0.000 claims description 8
- 238000012856 packing Methods 0.000 claims description 8
- 208000023482 precordial pain Diseases 0.000 claims description 7
- 241001061264 Astragalus Species 0.000 claims description 6
- 206010010970 Cor pulmonale chronic Diseases 0.000 claims description 6
- 235000006533 astragalus Nutrition 0.000 claims description 6
- 208000026636 chronic pulmonary heart disease Diseases 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000004321 preservation Methods 0.000 claims description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 208000031975 Yang Deficiency Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 201000008247 brain infarction Diseases 0.000 claims description 5
- 238000012869 ethanol precipitation Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 150000002212 flavone derivatives Chemical class 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229940093181 glucose injection Drugs 0.000 claims description 4
- 210000004233 talus Anatomy 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000011265 semifinished product Substances 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 25
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 201000006306 Cor pulmonale Diseases 0.000 abstract description 2
- 208000004186 Pulmonary Heart Disease Diseases 0.000 abstract description 2
- 241000132521 Erigeron Species 0.000 abstract 1
- 206010060840 Ischaemic cerebral infarction Diseases 0.000 abstract 1
- 229930195210 Ophiopogon Natural products 0.000 abstract 1
- 244000248557 Ophiopogon japonicus Species 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 230000010412 perfusion Effects 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 description 29
- 238000012360 testing method Methods 0.000 description 25
- 206010062717 Increased upper airway secretion Diseases 0.000 description 13
- 208000026435 phlegm Diseases 0.000 description 13
- 206010021143 Hypoxia Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- 201000006474 Brain Ischemia Diseases 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 206010008120 Cerebral ischaemia Diseases 0.000 description 10
- 230000002107 myocardial effect Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 210000000038 chest Anatomy 0.000 description 9
- 208000031225 myocardial ischemia Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 230000007954 hypoxia Effects 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 208000028867 ischemia Diseases 0.000 description 7
- 239000012567 medical material Substances 0.000 description 7
- 208000002815 pulmonary hypertension Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 206010061216 Infarction Diseases 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 6
- 230000007574 infarction Effects 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010061876 Obstruction Diseases 0.000 description 5
- 230000002612 cardiopulmonary effect Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000004089 microcirculation Effects 0.000 description 5
- 230000036284 oxygen consumption Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000008451 emotion Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000003657 middle cerebral artery Anatomy 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 210000001147 pulmonary artery Anatomy 0.000 description 4
- 210000005241 right ventricle Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 230000006793 arrhythmia Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- -1 stilbene saponin Chemical class 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000011800 void material Substances 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000005262 decarbonization Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 206010037437 Pulmonary thrombosis Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000003948 acquired polycythemia Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 208000030270 breast disease Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 229940074869 marquis Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 description 1
- QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 description 1
- 230000008065 myocardial cell damage Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229930190017 ophiopogonin Natural products 0.000 description 1
- 229930190714 ophiopogonone Natural products 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- VBUNOIXRZNJNAD-UHFFFAOYSA-N ponazuril Chemical compound CC1=CC(N2C(N(C)C(=O)NC2=O)=O)=CC=C1OC1=CC=C(S(=O)(=O)C(F)(F)F)C=C1 VBUNOIXRZNJNAD-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000001869 rapid Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000013213 secondary polycythemia Diseases 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000036301 sexual development Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410081470 CN1660261A (zh) | 2004-12-14 | 2004-12-14 | 复方麦芪注射剂及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410081470 CN1660261A (zh) | 2004-12-14 | 2004-12-14 | 复方麦芪注射剂及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1660261A true CN1660261A (zh) | 2005-08-31 |
Family
ID=35009998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410081470 Pending CN1660261A (zh) | 2004-12-14 | 2004-12-14 | 复方麦芪注射剂及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1660261A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406833A (zh) * | 2010-12-01 | 2012-04-11 | 成都中医药大学 | 一种麦冬的综合提取利用技术 |
CN109645481A (zh) * | 2018-12-18 | 2019-04-19 | 四川依科制药有限公司 | 麦冬须根提取物及其制备方法和用途 |
-
2004
- 2004-12-14 CN CN 200410081470 patent/CN1660261A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406833A (zh) * | 2010-12-01 | 2012-04-11 | 成都中医药大学 | 一种麦冬的综合提取利用技术 |
CN109645481A (zh) * | 2018-12-18 | 2019-04-19 | 四川依科制药有限公司 | 麦冬须根提取物及其制备方法和用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1939418A (zh) | 一种食药同源的中草药组合物 | |
CN102600423B (zh) | 用于治疗肝纤维化的中药制备方法 | |
CN108524673A (zh) | 一种中药组合物及其应用 | |
CN1771944A (zh) | 高溶解度黄连素在制药中的应用 | |
CN1817354B (zh) | 辛芪注射剂及制备方法 | |
CN1541676A (zh) | 一种产后补血保健药物及其制备方法和应用 | |
CN1679697A (zh) | 一种含有三七、瓜蒌皮、水蛭的治疗心血管疾病的中药制剂及其制备方法 | |
CN103735663B (zh) | 一种降血糖中药及其制备方法 | |
CN1660261A (zh) | 复方麦芪注射剂及制备方法 | |
CN107854609A (zh) | 红参、麦冬、五味子组合物用于制备治疗抑郁症的药物的用途 | |
CN104587387B (zh) | 一种预防和治疗三高症的组合中药与制备方法 | |
CN102988747B (zh) | 一种三刺降三高的冲剂及其制备方法 | |
CN104256618B (zh) | 一种降血糖的食品、保健品或药物组合物 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN102973726B (zh) | 一种用于高血压的中成药 | |
CN1679846A (zh) | 一种治疗心脏疾病的中药 | |
CN102579688B (zh) | 菊麻降压中药制剂 | |
CN100462082C (zh) | 灯盏细辛酮酯及其注射剂的制备方法 | |
CN107095977A (zh) | 一种具有祛火排毒功效的药剂及其药物配方和制备方法 | |
CN102772665B (zh) | 一种治疗阴虚内热型病毒性心肌炎的中药制剂及其制备方法 | |
CN1257728C (zh) | 用于治疗糖尿病的中成药及其制备方法 | |
CN102085324A (zh) | 一种治疗心肾不交证的中药组合物 | |
CN101045116A (zh) | 一种治疗胆囊炎的中药药物 | |
CN1615956A (zh) | 人参四逆注射剂及制备方法 | |
CN1935183A (zh) | 一种中药复方制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN SANMIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SANMIN PHARMACEUTICAL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD., LESHAN CITY Effective date: 20050923 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050923 Address after: Western Park (cooperative town), Chengdu hi tech Industrial Development Zone, Sichuan, China Applicant after: SICHUAN SANMING PHARMACEUTICAL Co.,Ltd. Address before: Sichuan province Leshan City Chunhua Road No. 393 Applicant before: SANMIN MIDICINE SCIENCE AND TECHNOLOGY DEVELOPMENT Co.,Ltd. LESHAN CITY SICHUAN PROV |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Luo Feifei Document name: Notice of first review |
|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Luo Feifei Document name: Fourth notice of examination advice |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |